Companies / TTX

TETRATHERIX LIMITED

ASX:TTXPharmaceuticals, Biotechnology & Life Sciences
53.0M shares on issueASX (delayed) · as of 28 July 2026$7.07price · delayed$377.1Mmarket cap · indicative
B
Dilution gradeprovisional — limited history

Runway 4–8 quarters; 2 cash raises in 24 months; share count grew 11% in 24 months

Cash runway7.2 quarters of funding
Share-count growth (24m)10.7%
Raise cadence (24m)2 cash raises
Options & rights overhang0.8% of shares
In-the-money supply0.0% of shares
Pending proposed issuesnone

TETRATHERIX LIMITED's ordinary share count grew 10.7% between September 2025 and June 2026, to 29M shares. The company raised capital twice in the 24‑month window for total disclosed proceeds of A$40.6M, most recently a Placement (with SPP) that raised A$15.6M in May 2026. Options and rights on issue could convert into 408,198 new shares, equal to 0.8% of the current share count, with 0% in the money at present. At the June 2026 quarter the company reported A$34.5M in available cash, covering 7.2 quarters at its recent spending rate. No proposed securities issues (Appendix 3B) are pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
0.8%
Max option dilution
0.0%
ITM option dilution
1
Raises · last 12 months
7.2 qtrs
Cash cover · over 4 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 53.0M per ASX (delayed) (28 July 2026).
50.9M51.7M52.5MJune 25Jan 26July 26Cash raise · 25 May 2026Cash raise · 30 June 2025

Cash runway

—
Cover not computed for the latest quarter.
$34.5M available cash at quarter ended 30 June 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 30 June 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
1 July 20263G · unquotedTTX : ORDINARY FULLY PAID29.5MAppendix 3G
22 June 20262A · quoted issueTTX : ORDINARY FULLY PAID29.5MAppendix 2A
18 June 20262A · quoted issueTTX : ORDINARY FULLY PAID29.4MAppendix 2A
2 June 20262A · quoted issueTTX : ORDINARY FULLY PAID29.3MAppendix 2A
31 Mar 20263G · unquotedTTX : ORDINARY FULLY PAID27.2MAppendix 3G
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

2 cash raises in the last 24 months · 1 in the last 12 months

$15.6M
Placement (with SPP)
25 May 2026 ACTIVE
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

0.8%
Total overhang · of current shares
0.0%
In the money · at current price
408k
Potential new shares
—
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

No director dealing notices (Appendix 3Y) on record.
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

21 July 2026$PQuarterly Activities/Appendix 4C Cash Flow Report
1 July 2026Notification regarding unquoted securities - TTX
22 June 2026Tutela Interim Study Results
22 June 2026Application for quotation of securities - TTX
21 June 2026SPP Results
18 June 2026Application for quotation of securities - TTX
9 June 2026Mandatory Escrow Release
8 June 2026Study Results Peptide-Polymer Patents
3 June 2026SPP Booklet
3 June 2026Placement Cleansing Notice
2 June 2026Application for quotation of securities - TTX
27 May 2026Proposed issue of securities - TTX
27 May 2026$PSuccessful Completion $15M Placement
25 May 2026$PTrading Halt
22 Apr 2026$PQuarterly Activities/Appendix 4C Cash Flow Report
31 Mar 2026Notification regarding unquoted securities - TTX
16 Mar 2026Tetratherix March Investor Presentation
15 Mar 2026$PPrecision medicine franchise launch and new revenue
9 Mar 2026$PTutelix Update
24 Feb 2026HY FY26 Letter

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.